Alessandro De Angelis

Alessandro De Angelis

Auto-generated profile, based on publicly available information

Alessandro De Angelis

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in European Respiratory Review
Verified
Journal Article
Open access
AAAlessandro De Angelis
Alessandro De Angelis
MMMartina Marchello
Martina Marchello
ATAngela Tramontano
Angela Tramontano
MCMarianna Cicchetti
Marianna Cicchetti
MNMattia Nigro
Mattia Nigro
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis is a chronic respiratory disease characterised by irreversible bronchial dilation, persistent productive cough and alternating periods of clinical stability and exacerbations. The distorted airways impair mucus clearance, making them susceptible to recurrent infections and chronic inflammation. Haemophilus influenzae is a common pathogen in bronchiectasis according to international registries. It employs several virulence mechanisms, including adhesion, intracellular invasion/survival, biofilm formation and evasion of antibiotic treatments, to establish infection. These mechanisms allow H. influenzae to persist in the respiratory tract and evade host immune defences. Although its role is well-documented in other airway diseases, the impact of H. influenzae in bronchiectasis remains incompletely understood. International guidelines do not recommend eradication therapy for H. influenzae upon first isolation, while this intervention is advised for Pseudomonas aeruginosa in such cases. Long-term immunomodulatory treatment with macrolides is an option for patients with bronchiectasis with chronic H. influenzae infection and frequent exacerbations, though it carries the risk of promoting antibiotic resistance and a Pseudomonas-enriched airway microbiome. Studies indicate significant negative interactions between P. aeruginosa and H. influenzae, suggesting a competitive relationship that can influence microbiome dynamics and potentially affect clinical outcomes. Currently, there is insufficient evidence to support vaccination against nontypeable H. influenzae in chronic airways disease. Despite its frequent detection in respiratory samples, the precise role of H. influenzae in bronchiectasis-related morbidity and disease progression is not fully understood and warrants further investigation. This review examines the impact of H. influenzae on bronchiectasis pathophysiology and progression, comparing its role in other chronic respiratory diseases.

31 October 2025 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
AAAlessandro De Angelis
Alessandro De Angelis
VAVincenzo Alberto Artuso
Vincenzo Alberto Artuso
SAStefano Aliberti
Stefano Aliberti
PGPieter Goeminne
Pieter Goeminne
Bronchiectasis is a chronic, complex, and heterogeneous respiratory disease characterized by irreversible bronchial dilation, persistent airway inflammation, and recurrent infections. Traditionally viewed from a lung-centered perspective, its pathophysiology has been explained by the “vicious cycle” hypothesis, later refined into the more dynamic concept of the “vicious vortex.” However, emerging evidence highlights the pivotal role of comorbidities in influencing disease progression, symptom burden, and prognosis. This review explores the evolving understanding of bronchiectasis by integrating comorbidities into current pathophysiological frameworks. We illustrate how coexisting conditions interact with components of the vicious vortex, amplifying airway inflammation, impairing host defenses, and disrupting clearance mechanisms. We summarize evidence on the prevalence, clinical impact, and prognostic significance of key comorbidities and discuss their implications for patient management. Finally, we emphasize the importance of an integrated, multidisciplinary approach and the emerging role of the treatable traits framework, which focuses on identifying clinically relevant, biologically measurable, and modifiable traits—regardless of whether they are etiological or nonetiological. In this sense, we propose a conceptual “Copernican Revolution” in bronchiectasis care: recognizing comorbidities not as secondary features, but as potential drivers of disease trajectory. By adopting this pragmatic strategy, clinicians can optimize quality of life, achieve patient-centered care, and improve outcomes in this condition.

27 February 2025 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
ESEdoardo Simonetta
Edoardo Simonetta
AAAlessandro De Angelis
Alessandro De Angelis
MSMargherita S. Silani
Margherita S. Silani
VPVeronica Polelli
Veronica Polelli
MNMattia Nigro
Mattia Nigro
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis and chronic rhinosinusitis are chronic diseases of the upper and lower respiratory tract characterised by both infective and inflammatory pathways. The two share many clinical, radiological, microbiological and pathophysiological aspects. Bronchiectasis and chronic rhinosinusitis may be characterised by different endotypes, with inflammation driven by either neutrophils and/or eosinophils. Although the two conditions may coexist, the prevalence of their association remains uncertain. To date, few studies have investigated the pathogenetic relationship between these disorders, with ambiguous results obtained in heterogeneous populations. Some findings suggest that patients with both chronic rhinosinusitis and bronchiectasis may have a heavier disease burden consisting of more exacerbations, more debilitating symptoms, higher radiological severity and worse quality of life. In light of this, identification of treatable traits is crucial and patients are likely to benefit from a multidisciplinary approach involving, among others, pulmonologists, ear-nose-throat physicians, respiratory physiotherapists and allergists/immunologists.

1 April 2026 in European Respiratory Review
Verified
Journal Article
Open access
AAAlessandro De Angelis
Alessandro De Angelis
PMPau Marrades
Pau Marrades
LPLidia Perea
Lidia Perea
RFRosa Faner
Rosa Faner
AIAlessandra Iorfida
Alessandra Iorfida
OVOriol Sibila Vidal
Oriol Sibila Vidal
Bronchiectasis is a chronic respiratory disease characterised by irreversible bronchial dilatation, persistent airway inflammation and recurrent infections. Symptoms, particularly cough, sputum production and dyspnoea, are the most immediate and patient-relevant expression of the disease, linking clinical presentation, airway biology and outcomes. While asthma and COPD management algorithms already integrate symptom burden into therapeutic decision-making, bronchiectasis care has historically relied on exacerbation history to guide preventive interventions. Over the past decade, an expanding body of evidence has demonstrated that daily symptoms mirror current infection and inflammation, profoundly impact quality of life, and predict future exacerbations. Comparative analyses across chronic lung diseases further highlight the central role of symptom monitoring in defining disease activity and risk. The updated European Respiratory Society guidelines translate this evidence into clinical practice, marking a paradigm shift from an exacerbation-driven to a symptom-centred and treatable-traits model. This review synthesises clinical, biological and therapeutic insights linking symptoms to bronchiectasis pathophysiology, disease activity and treatment response. We discuss how airway clearance, mucoactive therapy, antibiotics, pulmonary rehabilitation and targeted anti-inflammatory strategies, including dipeptidyl peptidase-1 inhibition, can address specific symptom profiles. We also mention the role of comorbidities and psychosocial management, establishing symptoms as the cornerstone of a holistic, multidimensional care approach. Recognising symptoms as both biomarkers of activity and therapeutic targets represents a major step toward precision medicine in bronchiectasis, aligning clinical management with patient experience and the biological drivers of disease.

31 July 2025 in ERJ Open Research
Verified
Journal Article
Open access
MCMarianna Cicchetti
Marianna Cicchetti
AAAlessandro De Angelis
Alessandro De Angelis
ESEdoardo Simonetta
Edoardo Simonetta
AGAndrea Gramegna
Andrea Gramegna
Paola FaverioPaola Faverio
Paola Faverio
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis is a heterogeneous chronic respiratory disease characterised by permanent bronchial dilation, daily productive cough and frequent exacerbations [1]. In recent years, the understanding of bronchiectasis has evolved beyond the paradigm of recurrent infections and structural lung damage. Systemic inflammation and coexisting comorbidities are now recognised as integral components of disease pathophysiology [2–4]. Moreover, patients increasingly emphasise the need for personalised and flexible management strategies, pointing out the limitations of a one-size-fits-all approach [5].

11 December 2025 in ERJ Open Research
Verified
Journal Article
Open access
AAAlessandro De Angelis
Alessandro De Angelis
ESEdoardo Simonetta
Edoardo Simonetta
PSPaola Scarano
Paola Scarano
ATAngela Tramontano
Angela Tramontano
MNMattia Nigro
Mattia Nigro
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis is a chronic respiratory condition characterised by irreversible bronchial dilatation, persistent respiratory symptoms and recurrent exacerbations [1]. Despite significant progress in understanding its pathophysiology, many diagnostic and therapeutic decisions remain based on expert opinion [2, 3]. In particular, the role of bronchoscopy remains debated. According to current guidelines, bronchoscopy should be considered in patients with nonproductive cough and signs of infection on computed tomography (CT), or when obstructive causes or nontuberculous mycobacterial pulmonary disease (NTM-PD) are suspected [2, 3].